Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
Earnings Data
Report Date
Mar 12, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.55Last Year’s EPS
-1.33Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted successful product launch and strong financial positioning, with significant revenue generation and advancements in clinical trials. However, continued expenses and the need for additional trial enrollment present challenges.Company Guidance
Strong Commercial Launch of AVMAPKI FAKZYNJA CO-PACK
Achieved $11.2 million in net product revenue in the third quarter, surpassing expectations. High levels of physician engagement and patient retention were noted, with 133 prescribers and prescriptions from both academic and community settings.
Advancement in Clinical Trials
Completed enrollment of the RAMP-205 expansion cohort for first-line pancreatic cancer and the confirmatory Phase III RAMP-301 trial in recurrent LGSOC. Cleared two monotherapy doses in the G12D program without dose-limiting toxicities.
Financial Stability
Ended the third quarter with $137.7 million in cash, cash equivalents, and investments. Expected runway into the second half of 2026 with ongoing commercial and clinical developments.
Broad Payer Coverage
Payer coverage exceeded 80% for the AVMAPKI FAKZYNJA CO-PACK, with a mix of commercial and Medicare payers, ensuring seamless access for patients.
VSTM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VSTM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $9.90 | $7.91 | -20.10% |
Aug 07, 2025 | $5.62 | $6.74 | +19.93% |
May 13, 2025 | $7.46 | $7.13 | -4.42% |
Mar 20, 2025 | $6.82 | $6.65 | -2.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Verastem (VSTM) report earnings?
Verastem (VSTM) is schdueled to report earning on Mar 12, 2026, After Close (Confirmed).
What is Verastem (VSTM) earnings time?
Verastem (VSTM) earnings time is at Mar 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VSTM EPS forecast?
VSTM EPS forecast for the fiscal quarter 2025 (Q4) is -0.55.